Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.
| Revenue (Most Recent Fiscal Year) | $389.13M |
| Net Income (Most Recent Fiscal Year) | $204.83M |
| PE Ratio (Current Year Earnings Estimate) | 32.78 |
| PE Ratio (Trailing 12 Months) | 38.69 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 19.91 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.30 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 36.35 |
| Pre-Tax Margin (Trailing 12 Months) | 48.69% |
| Net Margin (Trailing 12 Months) | 52.64% |
| Return on Equity (Trailing 12 Months) | 18.69% |
| Return on Assets (Trailing 12 Months) | 17.12% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.95 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.56 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.66 |
| Book Value per Share (Most Recent Fiscal Quarter) | $42.06 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.70 |
| Earnings per Share (Most Recent Fiscal Year) | $6.84 |
| Diluted Earnings per Share (Trailing 12 Months) | $6.85 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 29.23M |
| Free Float | 25.23M |
| Market Capitalization | $7.75B |
| Average Volume (Last 20 Days) | 0.30M |
| Beta (Past 60 Months) | 0.49 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.29% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |